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The advent of molecular biology has already 
transformed the landscape in endocrinol-
ogy. From the early days of molecular 
endocrinology, when techniques such as 
Southern blotting were used to detect large 
deletions, through the introduction of PCR 
and sequencing with the identification of 
variants in single genes, and finally to the 
present day when the focus is shifting to 
whole genome sequencing and identifica-
tion of epigenetic influences on phenotypic 
expression, represents a quantum leap in 
our knowledge and understanding of the 
genomic processes underlying normal-
ity and disease evolution. However, with 
increasingly sophisticated techniques 
becoming available, the challenges facing 
genomic and molecular endocrinology 
will become increasingly complex. We will 
attempt to discuss some of these chal-
lenges, which hopefully will be featured 
in future issues of Frontiers in Genomic 
Endocrinology.
A number of novel genes have been iden-
tified in association with a variety of endo-
crine phenotypes over the last few years. 
However, although mutations in a number 
of genes have been described in association 
with disorders such as hypogonadotropic 
hypogonadism, congenital hypopituitar-
ism, disorders of sex development, and con-
genital hyperinsulinism, these account for a 
minority of patients with these conditions, 
suggesting that many more genes remain to 
be identified. How will these novel genes be 
identified? Monogenic disorders can arise 
as a result of genomic microdeletions or 
microduplications, or due to single point 
mutations that lead to a functional change 
in the relevant protein. Such disorders may 
also result from altered expression of a gene, 
and hence altered dosage of the protein. 
Candidate genes may be identified by utiliz-
ing naturally occurring or transgenic mouse 
models, and this approach has been par-
ticularly informative in the elucidation of 
the genetic basis of a number of disorders. 
Other approaches include the identification 
of chromosomal rearrangements using con-
ventional karyotyping techniques, as well 
as novel assays such as array comparative 
genomic hybridization (CGH) and single 
nucleotide polymorphism oligonucleotide 
arrays (SNP arrays). These molecular meth-
ods usually result in the identification of 
gross abnormalities as well as submicro-
scopic deletions and duplications, and 
eventually to the discovery of single gene 
defects that are associated with a particular 
phenotype.
However, there is no doubt that the major 
advances in novel gene identification will be 
made as a result of the sequencing of the 
genome of affected individuals and com-
parison with control data that are already 
available. Chip techniques allow hybridiza-
tion of DNA or RNA to hundreds of thou-
sands of probes simultaneously. Microarrays 
are being used for mutational analysis of 
human disease genes. Complete sequenc-
ing of genomes or sequencing of exons that 
encode proteins (exome sequencing) is now 
possible, and will lead to the elucidation of 
the etiology of a number of human diseases 
in the next few years. High-throughput, 
high-density sequencing using microarray 
technology potentially offers the option of 
obtaining rapid, accurate, and relatively 
inexpensive sequence of large portions of 
the genome. One such technique is oligo-
hybridization sequencing, which relies on 
the differential hybridization of target DNA 
to an array of oligonucleotide probes. This 
technique is ideally suited to the analysis of 
DNA from patients with defined disorders, 
such as disorders of sex development and 
retinal disease, but suffers from a relatively 
high false positive rate and failure to detect 
insertions and deletions.
The greatest strides have been made 
in the area of next generation sequencing 
(NGS), which has made possible whole 
genome sequence analysis. A number 
of technologies are available, with more 
being developed. Template preparation, 
preparation of the sequencing reaction, 
the sequencing itself and the data handling 
and analyses are critical steps in NGS. The 
costs involved and the data handling skills 
required have currently restricted NGS 
to research laboratories. More targeted 
approaches such as exome capture, which 
analyses the sequence of coding exons only, 
or targeting specific chromosomes, such as 
the X-chromosome in potentially X-linked 
conditions, are becoming more widely 
available. NGS technologies are capable of 
identifying novel disease genes and struc-
tural chromosomal variations. For example, 
the molecular basis of recessive Charcot–
Marie–Tooth Neuropathy was identified in 
a pedigree using whole genome sequencing 
(Lupski et al., 2010).
The major challenges will be the inter-
pretation of vast amounts of data that will 
be generated using these techniques. It is 
quite likely that many disorders that are 
currently believed to be monogenic may 
in fact be digenic or oligogenic. For exam-
ple, hypogonadotropic hypogonadism 
has recently been shown, in some affected 
patients, to be a digenic disorder (Pitteloud 
et al., 2007). Additionally, many disor-
ders are inherited in a dominant fashion, 
with variability in clinical manifestations 
as a result of differences in penetrance or 
expressivity. The mechanisms underlying 
variable penetrance or expressivity remain 
to be established, but digenicity may cer-
tainly play a role. These phenomena may 
also reflect the effects of multiple genetic 
variations modifying disease expression, 
and/or interactions with environmental 
factors. Furthermore, the phenomenon of 
epigenetics may be implicated in the vari-
ability in penetrance. Gene expression can 
be influenced by epigenetic events, such as 
X-inactivation and imprinting. Epigenetic 
alterations and chemical modifications of 
DNA or chromatin proteins influence gene 
transcription. The sum of all epigenetic 
information defines the epigenome, which, 
in contrast to the genome, is highly variable 
between cells and changes within a single 
cell over time. Epigenetic modifications lead 
to phenotypic changes without alteration of 
DNA sequence, and may be heritable.
Genomic imprinting leads to preferen-
tial expression of an allele depending on 
its parental origin. In this situation, DNA 
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2006). Finally, we are now entering the era 
of pharmacogenetics when the response of 
an individual to various therapeutic agents 
may be determined by their genotype. For 
example, a polymorphism in the GH recep-
tor that results in deletion of exon 3 may 
be associated with an improved response 
to GH (Dos Santos et al., 2004). Thus the 
elucidation of the genetic basis of many 
disorders will aid their management, and 
permit the tailoring of therapy in individual 
patients.
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with height, these account for only ∼3–4% 
of the variance in adult height. Similar data 
exist for obesity. Hence the challenge must 
be to identify other factors associated with 
obesity and short stature. Additionally could 
the genetic variants identified to date account 
for more extreme phenotypes?
It is often difficult to perform studies in 
humans, and so the generation of animal 
models may be valuable in understanding 
the etiology and pathogenesis of disease. A 
number of naturally occurring mouse mod-
els have led to the identification of corre-
sponding candidate genes in humans, with 
mutations subsequently detected in human 
patients. More frequently, genes of interest 
are often deleted and lead to the generation 
of disease models. In general, mouse models 
correlate well with human disease; however 
species-specific defects need to be taken into 
account. Additionally, the transgenic mod-
els could be used to manipulate a condition, 
with the potential for new therapies. The 
advent of conditional transgenesis has led to 
an exponential increase in our understand-
ing of how the mutation of a single gene 
impacts on a single organ. Using technology 
such as inducible gene expression systems, 
the effect of switching on or switching off 
a gene at a particular stage in development 
can be determined.
Advances in genomics will also have a 
major impact on therapeutics. Micro RNAs 
(miRNA) are small non-coding RNAs 
that regulate gene expression by targeting 
mRNAs of protein coding genes or non-
coding RNA transcripts. Micro RNAs also 
have an important role in developmental 
and physiological processes and can act 
as tumor suppressors or oncogenes in the 
ontogenesis of cancers. The use of small 
interfering RNA (siRNA) offers promise 
of novel therapies in a range of condi-
tions, such as cystic fibrosis and Type II 
autosomal dominant IGHD (Shariat et al., 
2008). Elucidation of the genetic basis of 
disease also allows more direct targeting of 
therapy. For instance, children with per-
manent neonatal-onset diabetes mellitus 
(PNDM) due to mutations in SUR1 or 
KIR6.2 were previously treated with  insulin 
but have now been shown to respond well 
to sulfonylureas, thereby allowing the ces-
sation of insulin therapy (Pearson et al., 
methylation leads to silencing, i.e., sup-
pression of gene expression on one of the 
chromosomes. It is of importance in disor-
ders in which the transmission of disease 
is dependent on the sex of the transmit-
ting parent and has an important role in 
the expression of certain genetic disorders. 
The two classic examples are the Prader–
Willi and Angelman syndromes. Deletions 
in PWS occur exclusively on the paternal 
chromosome 15 whereas Angelman syn-
drome is due to deletions on the maternal 
chromosome 15. These two syndromes may 
also result from uniparental disomy, i.e., by 
the inheritance of either two maternal chro-
mosomes 15 (PWS) or two paternal chro-
mosomes (Angelman syndrome). Other 
imprinting disorders include pseudo- and 
pseudopseudohypoparathyroidism as well 
as Russell–Silver syndrome.
Many disorders have a complex etiology 
involving multiple genes (polygenic disorders), 
often in combination with environmental 
and lifestyle factors (multifactorial disorders). 
The major health care problems, cardiovas-
cular disease, hypertension, diabetes, obesity, 
asthma, and psychiatric disorders, fall into 
this category but it also includes certain devel-
opmental abnormalities, such as cleft palate, 
congenital heart defects, and neural tube 
defects. Compared with single gene defects, 
complex disorders have a low heritability and 
do not fit a Mendelian pattern of inheritance. 
Twin studies have been particularly helpful 
in demonstrating the importance of genetic 
and environmental factors. Susceptibility 
genes or loci can be mapped using several 
methods, including linkage analyses, associa-
tion studies, and affected sib-pair analyses. 
Current efforts aim to identify these genes 
by establishing correlations between SNPs 
or SNP haplotypes and complex disorders 
in large populations through Genome-wide 
Association studies, GWAS. The results of 
GWAS may, in part, depend on ethnicity 
and ascertainment criteria. Nevertheless, 
GWAS has been used in order to identify 
the genetic basis of a number of complex 
disorders. Human height is a classic, highly 
heritable, quantitative, polygenic trait; up to 
90% of normal variation in human height 
within populations is due to genetic variation. 
However, although GWAS studies have iden-
tified a number of genetic variants associated 
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